SCI-210

Autism CBD Trial On Children Advances As Israeli Company Enrolls First Five Patients
SciSparc Ltd. (NASDAQ: SPRC) announced on Tuesday that the first five patients have been enrolled and dosed into its ongoing clinical trial in children suffering from autism spectrum disorder (ASD) at the Soroka Medical Center in Israel. The Israeli specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system enrolled the first patient in its clinical trial assessing the efficacy and safety of its cannabidiol (CBD) – based drug for the treatment of children with autism spectrum disorder in March.
Autism CBD Trial Enrolls Children: This Israeli Co. Is Making Headway In New Treatments
The first patient has been enrolled in SciSparc Ltd.'s clinical trial evaluating the effectiveness and safety of their CBD-based drug for treating children with autism spectrum disorder, marking a significant advancement in ASD treatment. CEO Oz Adler expressed excitement about this milestone, highlighting the potential impact of the SCI-210 therapy in managing ASD symptoms. The company plans to enroll 60 participants aged 5 to 18 for a 20-week trial, comparing SCI-210 therapy with standard CBD treatment, in collaboration with the National Autism Research Center. Partnering with Tikun Olam Cannbit Pharmaceuticals Ltd., SciSparc aims to bring SCI-210 to market in Israel initially, with global distribution pending regulatory approvals. Additionally, the company achieved patent approvals in Canada for their opioid and n-acylethanolamine combination for pain management, as well as validation for their core technology patent in 15 European countries, demonstrating their commitment to advancing cannabinoid-based therapeutics.